Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Abdominal Fibromatosis
14%
Adjuvant Chemotherapy
14%
Aggressive Fibromatosis
14%
ALK Inhibitor
14%
All Cause Mortality
22%
Arm
14%
Cardio-Oncology
18%
Cardiotoxicity
21%
Chemoradiotherapy
14%
Chemotherapy
36%
Connective Tissue Cancer
17%
Diabetes Mellitus
14%
Diastolic Function
14%
Disease Free Survival
15%
Diseases
50%
Embolization
14%
Excision Repair Cross-Complementing
14%
Familial Adenomatous Polyposis
14%
Genetics
17%
Immune Checkpoint Inhibitor
84%
Immunotherapy
31%
Ipilimumab
14%
Krukenberg Tumor
14%
Liver Metastasis
20%
Lung Cancer
24%
Lymph Node
14%
Malignant Neoplasm
66%
Median Follow Up
16%
Medical Record
16%
Multivariate Analysis
20%
Myocarditis
18%
Neoadjuvant Therapy
21%
Neoplasm
14%
Neutropenia
14%
Nivolumab
42%
Non Small Cell Lung Cancer
100%
Non-Small Cell Lung Cancer
28%
Overall Survival
74%
Paclitaxel
14%
Pembrolizumab
41%
Platinum
20%
Progression Free Survival
42%
Prospective Study
14%
Real-World Data
21%
Rectum Cancer
14%
Retroperitoneal Sarcoma
28%
Retrospective Study
32%
Systolic Dysfunction
14%
Troponin
17%
Tumor
27%
Keyphrases
95% Confidence Interval
38%
Adenomatous Polyposis Coli
14%
All-cause Mortality
21%
Cancer Patients
17%
Cancer Therapy-related Cardiac Dysfunction (CTRCD)
28%
Cardio-oncology
18%
Cardiotoxicity
21%
Chemotherapy
22%
Clinical Outcomes
19%
Diastolic Function
14%
Doxorubicin
14%
Early Markers
14%
Familial Adenomatous Polyposis
14%
Genetic Polymorphism
14%
Immune Checkpoint Inhibitors
80%
Intra-arterial
14%
Life Perspective
14%
Liver
14%
Liver Metastasis
23%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
29%
Lung Cancer
21%
Lymph Node Ratio
14%
Median Overall Survival
16%
Medical Records
19%
Metastatic Non-small Cell Lung Cancer
14%
Microsphere Embolization
14%
Multivariate Analysis
20%
Myocarditis
18%
Neoadjuvant Chemoradiotherapy (nCRT)
21%
Neoadjuvant Therapy
21%
Neutropenia
14%
Nivolumab
28%
Non-small Cell Lung Cancer (NSCLC)
68%
Non-small Cell Lung Cancer Patients
16%
Overall Survival
48%
Paclitaxel
14%
Pathological Complete Response
14%
Pembrolizumab
39%
Potential Biomarkers
14%
Predictive Value
14%
Prognostic Value
16%
Progression-free Survival
17%
Real-life Data
16%
Rectal Cancer
14%
Retroperitoneal Sarcoma
14%
Sarcoma
14%
Systolic Dysfunction
14%
Trabectedin
14%
Treatment Lines
15%
World Data
21%